Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 2/20 | 0.34 |
| ▸ | HTR1B | P28222 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1454019 | 0.91 | KCNH2 (0.41) | KCNH2PRMT6LTA4HPGRHDAC1 | |
| SCHEMBL1453967 | 0.80 | KCNH2 (0.41) | KCNH2PRMT6LTA4HPGRHDAC1 | |
| SCHEMBL4651917 | 0.79 | HDAC2 (0.40) | KCNH2PRMT6PGRHDAC1HDAC2 | |
| SCHEMBL1453380 | 0.79 | KCNH2 (0.40) | KCNH2PRMT6LTA4HPGRHDAC1 | |
| SCHEMBL1454121 | 0.77 | HTR2C (0.34) | — | |
| SCHEMBL1453960 | 0.77 | PRMT6 (0.33) | KCNH2PRMT6LTA4HCYP17A1CYP11B1 | |
| SCHEMBL1454105 | 0.75 | QDPR (0.36) | PRMT6ERN1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL1452795 | 0.72 | LTA4H (0.36) | KCNH2LTA4H | |
| SCHEMBL1452902 | 0.71 | CHRNB2 (0.32) | — | |
| SCHEMBL1454482 | 0.69 | EDNRB (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910783-B2 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | SP1, TTL, TTLL12 | KCNH2 1293/4885PRMT6 1610/4885LTA4H 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.